Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.7.0.1
Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended 51 Months Ended
Sep. 14, 2015
Dec. 24, 2013
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2014
Mar. 31, 2017
Consulting and advisory fees       $ 6,250    
Aggregate principal cash obligation and commitments amount     $ 120,761     $ 120,761
Principal cash obligations and commitments included in current liabilities     42,233     42,233
Collaboration Agreement Bio PharmaWorks LLC [Member]            
Consulting and advisory fees     0      
Dr. Kathleen P. Mullinix [Member]            
Consulting and advisory fees       6,250 $ 25,000  
Collaboration Agreement Bio PharmaWorks LLC [Member]            
Consulting and advisory fees $ 10,000          
Theradex Systems, Inc [Member]            
Clinical costs charged to operations           $ 2,192,165
Collaboration Agreement Bio PharmaWorks LLC [Member]            
Consulting and advisory fees       30,000    
Theradex Systems, Inc [Member]            
Clinical costs charged to operations     64,615 116,633    
Theradex Systems, Inc [Member] | Phase 1 Clinical [Member]            
Estimated total clinical costs to be charged to operations     $ 2,200,000      
Percentage of clinical trial service     60.00%      
Percentage of clinical center laboratory cost     40.00%      
NDA Consulting Corp [Member]            
Consulting and advisory fees   $ 4,000 $ 4,000 $ 4,000